Get started
Author

Marlo A. Blazer

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
2014 · Marlo Blazer, Christina Wu, et al. · Annals of Surgical Oncology · 244
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma
2019 · Ajai Chari, Dorothy Romanus, et al. · Clinical Lymphoma Myeloma & Leukemia · 107
PDF
A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis
2016 · Daniel H. Ahn, Kavya Krishna, et al. · Therapeutic Advances in Medical Oncology · 59
PDF
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
2020 · Ajai Chari, Paul G. Richardson, et al. · Expert Review of Hematology · 43
PDF
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States
2018 · Parameswaran Hari, Dorothy Romanus, et al. · Clinical Lymphoma Myeloma & Leukemia · 42
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies
2017 · Parameswaran Hari, Dorothy Romanus, et al. · Journal of Geriatric Oncology · 42
PDF
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States
2018 · Jill A. Bell, Aaron Galaznik, et al. · Leukemia Research · 36
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
2021 · Faith Davies, Robert Rifkin, et al. · Annals of Hematology · 34
PDF
Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases
2012 · Ludmila Katherine Martin, Anthony Cucci, et al. · Clinical Colorectal Cancer · 29
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
2013 · Candice M. Wenzell, Michael J. Berger, et al. · Supportive Care in Cancer · 25
Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience.
2015 · Kavya Krishna, Marlo A. Blazer, et al. · Journal of Clinical Oncology · 22
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
2018 · Jill A. Bell, Aaron Galaznik, et al. · PharmacoEconomics - Open · 19
PDF
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent
2019 · Jill A. Bell, Aaron Galaznik, et al. · Leukemia Research · 18
PDF
Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).
2014 · Marlo A. Blazer, Christina Sing-Ying Wu, et al. · Journal of Clinical Oncology · 15
A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
2015 · C Wu, S Mikhail, et al. · British Journal of Cancer · 11
PDF
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
2019 · David Campbell, Marlo Blazer, et al. · PubMed Central · 10
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care
2018 · Jill A. Bell, Aaron Galaznik, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting: A Matched-Claims Analysis of Patients With Breast, Colorectal, and Lung Cancers
2018 · Lucio Gordan, Marlo Blazer, et al. · Journal of Oncology Practice · 9
Cost differential of immuno-oncology therapy delivered at community versus hospital clinics.
2019 · Lucio Gordan, Marlo Blazer, et al. · PubMed · 8
Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience
2017 · Ajai Chari, Dorothy Romanus, et al. · Blood · 8
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil–Induced Cardiac Vasospasm
2015 · Craig A. Vargo, Marlo Blazer, et al. · Clinical Colorectal Cancer · 8
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting
2013 · Sherry Mori-Vogt, Marlo Blazer · Expert Review of Anticancer Therapy · 6
Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA
2018 · Parameswaran Hari, Marlo Blazer, et al. · Expert Review of Hematology · 4
Ps1419 Comparative Effectiveness of Triplets Containing Bortezomib (b), Carfilzomib (c), Daratumumab (d), or Ixazomib (i) in Relapsed/refractory Multiple Myeloma (rrmm) in Routine Care in the Us
2019 · F. Davies, R. Rifkin, et al. · HemaSphere · 3
Randomized Clinical Trial (RCT) Representativeness and Outcomes Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated in the Real World (RW): Comparison of ASPIRE, TOURMALINE MM1, POLLUX, AND ELOQUENT-2 RCTS
2018 · Ajai Chari, Dorothy Romanus, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Works count: 44
Citation count: 826
H-index: 14
I10-index: 17
Year
Topic
Type